Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.

de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L, CodeBreaK 200 Investigators.

Open source

DOI
10.1080/14796694.2025.2474789
Published
2025-03-24
Container
Future Oncol
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2025.2474789,
  title = {Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.},
  author = {de Langen AJ and  Johnson ML and  Mazieres J and  Dingemans AC and  Mountzios G and  Pless M and  Wolf J and  Schuler M and  Lena H and  Skoulidis F and  Yoneshima Y and  Kim SW and  Linardou H and  Novello S and  van der Wekken AJ and  Chen Y and  Peters S and  Felip E and  Solomon BJ and  Ramalingam SS and  Dooms C and  Lindsay CR and  Ferreira CG and  Blais N and  Obiozor CC and  Wang Y and  Mehta B and  Varrieur T and  Ngarmchamnanrith G and  Stollenwerk B and  Waterhouse D and  Paz-Ares L and  CodeBreaK 200 Investigators.},
  year = {2025},
  journal = {Future Oncol},
  doi = {10.1080/14796694.2025.2474789},
  url = {https://doi.org/10.1080/14796694.2025.2474789}
}

RIS

TY  - JOUR
TI  - Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.
AU  - de Langen AJ
AU  -  Johnson ML
AU  -  Mazieres J
AU  -  Dingemans AC
AU  -  Mountzios G
AU  -  Pless M
AU  -  Wolf J
AU  -  Schuler M
AU  -  Lena H
AU  -  Skoulidis F
AU  -  Yoneshima Y
AU  -  Kim SW
AU  -  Linardou H
AU  -  Novello S
AU  -  van der Wekken AJ
AU  -  Chen Y
AU  -  Peters S
AU  -  Felip E
AU  -  Solomon BJ
AU  -  Ramalingam SS
AU  -  Dooms C
AU  -  Lindsay CR
AU  -  Ferreira CG
AU  -  Blais N
AU  -  Obiozor CC
AU  -  Wang Y
AU  -  Mehta B
AU  -  Varrieur T
AU  -  Ngarmchamnanrith G
AU  -  Stollenwerk B
AU  -  Waterhouse D
AU  -  Paz-Ares L
AU  -  CodeBreaK 200 Investigators.
PY  - 2025
JO  - Future Oncol
DO  - 10.1080/14796694.2025.2474789
UR  - https://doi.org/10.1080/14796694.2025.2474789
ER  - 

APA

AJ, D. L., ML, J., J, M., AC, D., G, M., M, P., J, W., M, S., H, L., F, S., Y, Y., SW, K., H, L., S, N., AJ, V. D. W., Y, C., S, P., E, F., BJ, S., SS, R., C, D., CR, L., CG, F., N, B., CC, O., Y, W., B, M., T, V., G, N., B, S., D, W., L, P., & Investigators., C. 2. (2025). Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.. Future Oncol. https://doi.org/10.1080/14796694.2025.2474789

Source records